about
The Role of Mitochondrial Reactive Oxygen Species in Cardiovascular Injury and Protective StrategiesFcγ and Complement Receptors and Complement Proteins in Neutrophil Activation in Rheumatoid Arthritis: Contribution to Pathogenesis and Progression and Modulation by Natural ProductsExploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular DiseaseNitric oxide, oxidative stress, and p66Shc interplay in diabetic endothelial dysfunctionThe role of iron-induced fibrin in the pathogenesis of Alzheimer's disease and the protective role of magnesiumMultiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)Beyond oxidative stress: an immunologist's guide to reactive oxygen speciesReactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical IndicationsAntioxidants and coronary artery disease: from pathophysiology to preventive therapyPost-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegenerationLiposomal Antioxidants for Protection against Oxidant-Induced DamageRegulation of signal transduction by reactive oxygen species in the cardiovascular systemTetramethylpyrazine ameliorates high glucose-induced endothelial dysfunction by increasing mitochondrial biogenesis.Nrf2 and the promotion of atherosclerosis: lessons to be learnedReactive Oxygen Species/Nitric Oxide Mediated Inter-Organ Communication in Skeletal Muscle Wasting Diseases.Calcific aortic valve stenosis: methods, models, and mechanismsAre the effects of alpha-glucosidase inhibitors on cardiovascular events related to elevated levels of hydrogen gas in the gastrointestinal tract?Time course and dose response of alpha tocopherol on oxidative stress in haemodialysis patients.Oxidative Stress Genes, Antioxidants and Coronary Artery Disease in Type 2 Diabetes Mellitus.Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH)Interactions of hyperhomocysteinemia and T cell immunity in causation of hypertensionThe use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatmentTrace elements in glucometabolic disorders: an update.Cysteine/cystine redox signaling in cardiovascular disease.Astaxanthin: a potential therapeutic agent in cardiovascular diseaseUnderstanding nutritional epidemiology and its role in policy.Astaxanthin, oxidative stress, inflammation and cardiovascular disease.Oxidative Stress and Inflammation in Heart Disease: Do Antioxidants Have a Role in Treatment and/or Prevention?Oxidative balance score and oxidative stress biomarkers in a study of Whites, African Americans, and African immigrants.L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway.Reactive Secondary Sequence Oxidative Pathology Polymer Model and Antioxidant Tests.Recruitment of the adaptor protein Nck to PECAM-1 couples oxidative stress to canonical NF-κB signaling and inflammation.Lipophilic compound-mediated gene expression and implication for intervention in reactive oxygen species (ROS)-related diseases: mini-reviewPolymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosisHyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes.The voltage-gated proton channel Hv1 enhances brain damage from ischemic stroke.Cardiac aging: from molecular mechanisms to significance in human health and diseaseFolate receptor-targeted antioxidant therapy ameliorates renal ischemia-reperfusion injury.Epigenetic Regulatory Effect of Exercise on Glutathione Peroxidase 1 Expression in the Skeletal Muscle of Severely Dyslipidemic Mice.Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems.
P2860
Q26747310-C2F06280-BC4B-4AC5-A8A1-56DA724E4932Q26783178-B5663E90-B20A-47F9-B914-66C869C13CBCQ26801173-D3287734-0137-4D57-8B47-74FE7FAE4E1FQ26830607-2C28D71C-B1FE-438B-A508-C744E82AEAD2Q26859190-251B1B8C-ABD3-4413-A459-D840C1E2A644Q27007515-43FDA674-5CE7-4DA6-9A01-C79CECAFECC0Q27011356-5CCA17B0-4E16-4A1F-9AA7-44D73E339E75Q27024762-1B5E555E-635F-48F7-883F-A866C4BD89F5Q27025669-F056FD31-7A03-4A0B-B670-EAA402258640Q27323209-EB09FB20-548F-48BB-9ADB-12F881085DB9Q28391211-A730CCEA-0B35-4224-9E9D-D9A3C32216D5Q28391569-687E6D19-7EFF-46F3-94E5-9E1B952E45CCQ28539558-90F112ED-FF08-4239-87E7-859AA20E95B4Q29541148-3956CDBC-A62E-4071-BC08-8B3D9C3CD4FCQ30275433-A88F2ED5-25B2-449B-BD57-93C83CB92F98Q30503246-D29BD38C-6E00-4349-852D-9F1A420860F6Q33442816-9DC09068-537F-43A8-8389-F3AFC501A6A7Q33511679-AA465758-1D28-4EA7-B6A5-EE37CE0D2017Q33659216-7540A1B8-4765-4E57-80D7-97649A5FC12EQ33755566-C5DFFAF4-2508-4698-8700-FC9D94762FCEQ33920630-2A91EAF1-6139-4ABF-8C28-78542003598DQ34411758-1C95ED90-457A-4C41-8302-80FC6B2E7F87Q34504189-5B7071A1-D95B-44F8-8830-91295BF43642Q34580141-DACC75F6-6770-49B1-8042-6E2EBEC32974Q34629065-E243B1D7-B457-4409-9C54-2E72E8D11E3EQ34884548-7533C0EB-E4B0-4E53-91D9-EEAB95030B45Q34995729-0B9672EB-A44A-487C-9A3E-B322F9EB85C2Q35167634-FA8A3940-4F01-41E8-94F0-8B24362F2881Q35198505-3654D5B5-5E8D-46A7-A5CA-696F6A976F34Q35199067-31C219B6-E2ED-4B6D-A9FF-9E654CFC29FAQ35504522-13A141B1-E140-4798-99FA-90E89D763555Q35551178-4ED35496-CAEB-421D-ADA4-5CC551270F27Q35671000-431ECA6C-F9BE-423C-A5C6-91714039DC01Q35710262-95EC12A8-2C3D-4A7E-800E-FADDAADBB2FAQ35830289-BF9288B4-0A22-4A33-A1F9-4441D65FD3EBQ35857080-C3A6A7A2-B77A-4433-A9E2-80622F43E9A1Q35898648-CFA570B2-8365-459B-9664-73357D2B69E8Q35917491-418E226E-FF23-4B3E-8185-9B25DB4C7A60Q35968920-BECFB6B7-F548-47E4-9CF0-682A04BF5BA1Q36023685-D1BBD5C9-2F52-4C82-931C-462901FE7462
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Why have antioxidants failed in clinical trials?
@en
Why have antioxidants failed in clinical trials?
@nl
type
label
Why have antioxidants failed in clinical trials?
@en
Why have antioxidants failed in clinical trials?
@nl
prefLabel
Why have antioxidants failed in clinical trials?
@en
Why have antioxidants failed in clinical trials?
@nl
P1476
Why have antioxidants failed in clinical trials?
@en
P2093
Steven R Steinhubl
P304
P356
10.1016/J.AMJCARD.2008.02.003
P407
P577
2008-05-01T00:00:00Z